businesspress24.com - Havn Life Sciences announces $5.46 million warrant exercise
 

Havn Life Sciences announces $5.46 million warrant exercise

ID: 1562543

(firmenpresse) - November 24, 2020, Vancouver, BC - Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the Company or Havn Life) is pleased to announce that 10,927,856 common share purchase warrants (Warrants) have been exercised (Exercise), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private placement that closed on June 5, 2020 and were subject to an accelerated exercise period as a result of the Companys share price remaining above $0.75 for a period of 10 consecutive trading days.

The Company notes that certain of the Warrants were sold by their original holders to third party buyers (the Buyers) prior to the Exercise thereof, including, a Buyer introduced by Canaccord Genuity Corp. to which the Company paid a cash commission of $80,000 or 8% of the subject exercise proceeds.

In addition to the recently announced voluntary escrow agreement, the team is elated to have received such strong support from existing shareholders through the exercise of warrants and from new shareholders through the warrant purchases and immediate exercise, said CEO, Tim Moore. This capital will allow Havn Life to continue to push towards its 2021 development strategy. On behalf of the Havn Life team, I would like to thank our dedicated shareholders for the unwavering support.

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Contact:
Investor Relations: ir(at)havnlife.com 604 687 7130
Media: brittany(at)exvera.com 778 238 6096





The CSE has not reviewed, approved or disapproved the content of this press release



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:





PresseKontakt / Agentur:



Bereitgestellt von Benutzer: irw
Datum: 24.11.2020 - 08:03 Uhr
Sprache: Deutsch
News-ID 1562543
Anzahl Zeichen: 3370

contact information:
Contact person:
Town:

Wien


Phone:

Kategorie:

Business News


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 203 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Havn Life Sciences announces $5.46 million warrant exercise

"
steht unter der journalistisch-redaktionellen Verantwortung von

Havn Life Sciences Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Havn Life Sciences Inc.



 

Who is online

All members: 10 568
Register today: 0
Register yesterday: 1
Members online: 0
Guests online: 63


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.